Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As is clearly known, this stock cannot be traded at this point anyway and all of the
Negatives theories about this company have already been posted on here many times. Seems like beating a dead horse to continue posting right now.
Just curious, why do you still follow this message board? Thanks.
Just curious, why do you still follow this message board? Thanks.
Just curious, why do you still follow this message board? Thanks.
I was a big believer in Double Crown and their Translock product. However, they got a United States patent to Translock about 3 years ago but still no licensing deal(s). How can that be? Also management does not update its shareholders adequately since they became delisted. We have no idea whatsoever if the company is currently working on licensing offers or ever had any licensing offers for Translock. However, when DDCC stock was trading, the company always put out these grand press releases discussing events getting investors hopes up but which almost never materialized. Now that the company stock is delisted and not trading, the company is almost always silent. The more time that goes on the less likely a deal gets done. What is wrong with the managment team. Shaking my head. Very frustrating.
Short seller volume in Aezs appears to be decreasing to very low levels according to recent reports. Short sellers must be getting scared of buyout of Aezs or licensing deal likely being imminent. https://fintel.io/ss/us/aezs
Even more institutional buying of Aezs recently. Morgan stanley reports 87.84% increase in ownership of Aezs shares. More institutional buying to come i'm sure. https://fintel.io/soh/us/aezs/morgan-stanley
Institutional ownership in Aezs is now at about 3,183,812 shares of the 16,400,000 share float, such that institutional ownership is up to about 19.5% of the outstanding float of Aezs. The institutional ownership has jumped significantly recently due to purchases by Goldman Co. of 1,000,000 shares of Aezs and 1,000,000 shares of Aezs by Broadview Partners LP. I think that Goldman Co. and Broadview Partners LP are related companies. https://fintel.io/so/us/aezs
AEZS rating increased to BUY at Valueengine. https://www.google.com/amp/s/www.fairfieldcurrent.com/news/2019/02/04/aeterna-zentaris-aezs-rating-increased-to-buy-at-valuengine.html/amp
The stock does seem very manipulated and i agree it should be trading at least in the $5-$7 range right now. It also doesnt help that all of the financial analysts are low balling the price targets for Aezs and not even discussing the possibilty of a buyout. However, i believe that either a buyout or licensing deal should happen very soon and the stock price will soar much higher.
Some important quotes in this press release from yesterday's news regarding European approval of Macrilen (Macimorelin) https://www.streetinsider.com/dr/news.php?id=15012128
H.C. Wainwright upgraded Aezs price target to $5.50. I think the price of Aezs will go much higher than that very soon in a buyout or licensing deal. https://www.google.com/amp/s/pressoracle.com/news/2019/01/17/aeterna-zentaris-aezs-receives-buy-rating-from-hc-wainwright.html/amp
You're right it doesn't say and can't access the decision without ordering it. I didnt realize the headline didnt specify what the decision was. I am very confident that the European Commission approved Macrilen and that Aezs will likely release a PR in the next few days saying so. Sorry for the confusion.
Looks as though Macrilen (Macimorelin) has been officially approved in Europe today. Great news for AEZS. http://ec.europa.eu/transparency/regdoc/index.cfm?fuseaction=list&n=10&adv=0&coteId=3&year=&number=&dateFrom=2019-01-11&dateTo=2019-01-11&serviceId=&documentType=&title=&titleLanguage=&titleSearch=EXACT&sortBy=NUMBER&sortOrder=DESC&p=6&
Thank you for the reply and your opinion. However, i do not think you have proven that DDCC management made money from selling their shares of DDCC. I still think with the hundreds of millions of shares that DDCC management owned at the time of the delisting it would appear to me that DDCC lost quite a bit of money from the stock being delisted. Thus, in my opinion, it is not only in the best interest of the shareholders for DDCC DDCC stock to come back to trading but I also believe that DDCC also really wants to get the stock back to trading as well to recoup their sizable losses.
We are now at day 263 of the European drug approval process. Standing committee consultation should have finished their consultation by January 5th according to EMA guidelines. The ball is now in the European Commisions court now and they have deadline of January 21 (day 277) to report their final decision of Macrilen drug approval in Europe. Thus, Macrilen could conceivably be approved in Europe any day now up until the deadline of January 21st! https://www.ema.europa.eu/documents/presentation/marketing-authorisation-evaluation-process-dr-evdokia-korakianiti_en.pdf
You're a clown lol
Wrong. Wrong and wrong. You couldn't be more wrong. Aezs stock is still a huge bargain at the current price. We could see $6-$7 on European approval of Macrilen as early as this week. Then i think Aezs immediately after European approval will either enter into a big licensing deal for Macrilen and the share price will go to $12-$15 or alternatively AEZS will get bought out by Novo Nordisk or other big pharma for $18-20 per share. These are just my opinions. Do your own research and due diligence.
I can't imagine too many people made money with DDCC. Looks like everyone lost with this stock including managment. Management owns hundreds of millions of shares of DDCC stock which is now worthless at least for the time being.
How did DDCC take the money and run?? DDCC management and board of directors owned a lot of DDCC shares which are now delisted. It didnt appear that There was much selling going with DDCC stock in 2016 until it was delisted in June 2017. Volume rarely was above 150,000 shares per day as i remember it in that time period. In other words, not only did shareholders lose money but so did DDCC management and board of directors it would appear.
I strongly believe that DDCC will find a way to come back to trading. I don't know exactly when but i think they will find a way to come back. Translock is a game changing invention in the shiping and mining industry and DDCC still has a lot of years left on its patent term for Translock remaining. Too great of an invention to just let it go. They will find a way. These are just my opinions. Do your own due diligence and research.
Lets be clear, it hasn't been actually proven this company is a scam. It is all speculation and guesses that they are a scam. Clearly, DDCC has been very poorly managed and has done a lousy job with promoting such a promising game changing invention such as Translock. Maybe they couldnt afford to file their financials. Who knows. Maybe their PR's were true. Who Knows. Maybe they will come back in the near future. You never know.
AEZS's drug Macrilen is the safest, most effective, most reliable, most accurate and easiest to use test for diagnosing adult growth hormone deficiency (AGHD) and is the only FDA approved drug for diagnosing AGHD. Macrilen should very soon be approved in Europe next month.
The human growth hormone market is expanding and is likely to reach $7.1 billion dollar valuation by 2025. Novo Nordisk who recently purchased the commercial rights to Macrilen in North America is recognozed as one of the top key players in the Human Growth Hormone market. Asian market for Human Growth Hormone is expected to be one of the biggest expanding markets for Human Growth Hormone over the next few years. http://www.abnewswire.com/pressreleases/human-growth-hormone-market-size-is-likely-to-reach-a-valuation-of-around-usd-71-billion-by-2025-grand-view-research-inc_240024.html
Michael Ward current CEO of AEZS, prior to AEZS served as Chief Compliance & Legal Officer and Corporate Secretary to Sagent Pharmaceuticals, and handled its sale to Nichi-iko Pharmaceuticals, Ltd. for $736 Million Dollars in 2016. Michael Ward is a deal maker. He was brought into AEZS for the purpose of selling the company in my opinion. Some strong indications that AEZS will be sold in its entirety are the settlement of two lawsuits in the past month right before Macrilen approval in Europe, no mention of expanding AEZS drug pipeline to any other drugs besides Macrilen, very little news and talk about the future of AEZS, and the very strong need by Novo Nordisk for Macrilen to compliment its drugs for treating AGHD. As always, do your own due diligence.
AEZS has settled two lawsuits in the past month. That is no coincidence in my opinion. AEZS by having now settled those lawsuits is paving the way to sell the company to most likely Novo Nordisk immediately after Macrilen gets approval in Europe next month in my opinion. As always, do your own due diligence.
BIG news for both Aterna Zentaris (AEZS) and Strongbridge (SBBP). Strongbridge deal with Novo Nordisk for Macrilen rights in the USA and Canada has officially closed. Lets get this party started!!! https://globenewswire.com/news-release/2018/12/19/1669400/0/en/Strongbridge-Biopharma-plc-Announces-Closing-of-Transaction-with-Novo-Nordisk-to-Transfer-the-Rights-to-MACRILEN-macimorelin-in-the-United-States-and-Canada.html
MAJOR news for AEZS: Strongbridge announces the official closing of the deal with Novo Nordisk for Macrilen in the USA and Canada. Lets gets this party started!!! https://globenewswire.com/news-release/2018/12/19/1669400/0/en/Strongbridge-Biopharma-plc-Announces-Closing-of-Transaction-with-Novo-Nordisk-to-Transfer-the-Rights-to-MACRILEN-macimorelin-in-the-United-States-and-Canada.html
I am holding all my shares of AEZS for the European approval of Macrilen which should happen next month and then buyout of AEZS or big licensing deal for Macrilen worldwide outside of North America which should happen in February 2019. I think that the price of AEZS could reach $4-$5 this month and then can reach $6-$8 in January upon Macrilen approval in Europe. I'm thinking that AEZS will be bought out by Novo Nordisk or other big pharma for $15-$18 per share in February 2019. These are just my opinions. Always do your own due diligence.
We should be hearing news any day now this month about the official closing of the Novo Nordisk deal with Strongbridge announced October 31, 2018 which should drive up the price of AEZS even further.
Can't imagine a pharmaceutical giant like Novo Nordisk only wanting the rights to Macrilen in USA and Canada. Novo Nordisk as mentioned in their October 31, 2018 press release really needs Macrilen to compliment its drug Norditropin. Therefore, Novo Nordisk will most certainly also want to acquire full worldwide rights to Macrilen outside of the USA and Canada as well. Novo Nordisk was most likely waiting to make sure that Macrilen got approved in Europe before buying out AEZS or making a huge licensing deal with AEZS for Macrilen. Now after last Fridays news, European approval of Macrilen is basically an absolute certainty within the coming weeks. Thus, to me its a no brainer that Novo Nordisk will buy out AEZS within the next two to three months from now. By buying out AEZS instead of doing a big licensing agreement for Macrilen outside of the USA and Canada, Novo Nordisk can save on the royalties it would have had to pay AEZS for the sales of Macrilen in the USA and Canada. The buyout makes the most sense for both Novo Nordisk and AEZS. http://press.novonordisk-us.com/News-Releases?item=122951
The deal between Novo Nordisk and Strongbridge Biopharma on October 31, 2018 changed everything for. AEZS for the better. According to the deal, Novo Nordisk paid $181.7 million dollars upfront to Strongbridge (SBBP) for Macrilen rights only in USA and Canada, not including Royalties Novo Nordisk must pay to both AEZS and SBBP for Macrilen sales in the USA and Canada. Macrilen value is now through the roof. AEZS still has FULL worldwide rights to Macrilen outside the USA and Canada. Imagine what Novo Nordisk or other big pharma will pay AEZS for Macrilen rights worldwide outside of the USA and Canada such as in Europe, Asia, etc. Market cap for Aezs is currently under $50 million dollars. Lots of room for the share price and market cap of Aezs to grow. Aezs share price in my opinion could easily reach $9-$11 on a buyout within the next two to three months. https://globenewswire.com/news-release/2018/10/31/1640246/0/en/Strongbridge-Biopharma-plc-Enters-into-Agreement-for-Novo-Nordisk-to-Acquire-the-U-S-and-Canadian-Rights-to-MACRILEN-macimorelin.html
Novo Nordisk recently paid $181 million dollars upfront for the commercial rights to Macrilen for only the USA and Canada not including royalties that Novo will pay to both AEZS and SBBP for sales of Macrilen in the USA and Canada. AEZS still controls FULL rights to Macrilen worldwide outside of the USA and Canada. Can you imagine what Novo Nordisk or other big Pharma will pay AEZS for the rights to Macrilen in Europe, Asia, and other markets worldwide outside of the USA and Canada. Market cap is only about 40 Million dollars right now. Imagine how much AEZS share price and market cap will grow soon. HUGE news today. Great investment.
NEWS out this morning. MACRILEN got the recommendation for approval in Europe. AMAZING News for AEZS and its shareholders!!!
Good morning fellow AEZS longs. Today should be the beginning of many exciting days for Aezs. With this recommendation for Macrilen's approval in Europe, which I expect to be announced at some point this morning, AEZS will be well on its way to reaching new highs in share price and exposure. Many more Big pharmsceutical companies, investors, institutions, and financial analysts will take notice of AEZS. It should be very smooth sailing ahead for AEZS. Great investment.